A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT06946797 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06946797
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-19
- Primary completion
- 2027-02-05
- Enrollment
- 76
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.